Literature DB >> 3136015

Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2.

S Thorsen1, M Philips, J Selmer, I Lecander, B Astedt.   

Abstract

Highly purified plasminogen-activator inhibitors of type 1 (PAI-1) and type 2 (PAI-2), low-Mr form, were compared with respect to their kinetics of inhibition of tissue-type (t-PA) and urokinase-type plasminogen activator (u-PA). The time course of inhibition of plasminogen activator was studied under second-order or pseudo-first-order conditions. Residual enzyme activity was measured by the initial rate of hydrolysis of a chromogenic t-PA or u-PA substrate or by an immunosorbent assay for t-PA activity. PAI-1 rapidly reacted with single-chain t-PA as well as with two-chain forms of t-PA and u-PA. The second-order rate constant k for inhibition of single-chain t-PA (5.5 x 10(6) M-1 s-1) was about three times lower than k for inhibition of the two-chain activators. PAI-2 reacted slowly with single-chain t-PA, k = 4.6 x 10(3) M-1 s-1. The association rate was 26 times higher with two-chain t-PA and 435 times higher with two-chain u-PA. The k values for inhibition of single-chain t-PA, two-chain t-PA and two-chain u-PA were respectively, 1200, 150 and 8.5 times higher with PAI-1 than with PAI-2. The removal of the epidermal growth factor domain and the kringle domain from two-chain u-PA did not affect the kinetics of inhibition of the enzyme, suggesting that the C-terminal proteinase part of u-PA (B chain) is responsible for both the primary and the secondary interactions with PAI-1 and PAI-2. The k values for inhibition of single-chain t-PA and endogenous t-PA in plasma by PAI-1 or PAI-2 were identical indicating that t-PA in blood consists mainly in its single-chain form.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3136015     DOI: 10.1111/j.1432-1033.1988.tb14162.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  25 in total

Review 1.  Molecular basis of thrombolytic therapy.

Authors:  H R Lijnen; D Collen
Journal:  J Nucl Cardiol       Date:  2000 Jul-Aug       Impact factor: 5.952

2.  Active α-macroglobulin is a reservoir for urokinase after fibrinolytic therapy in rabbits with tetracycline-induced pleural injury and in human pleural fluids.

Authors:  Andrey A Komissarov; Galina Florova; Ali Azghani; Sophia Karandashova; Anna K Kurdowska; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-08-30       Impact factor: 5.464

3.  Alpha 2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells.

Authors:  R W Stephens; H Tapiovaara; T Reisberg; J Bizik; A Vaheri
Journal:  Cell Regul       Date:  1991-12

Review 4.  Trends and future developments in the pharmacological treatment of acute ischaemic stroke.

Authors:  G J del Zoppo; S Wagner; M Tagaya
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

5.  Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro.

Authors:  T D Brooks; J Slomp; P H Quax; A C De Bart; M T Spencer; J H Verheijen; P A Charlton
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

6.  Regulation by interleukin-3 of human monocyte pro-inflammatory mediators. Similarities with granulocyte-macrophage colony-stimulating factor.

Authors:  P H Hart; G A Whitty; D R Burgess; J A Hamilton
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

7.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

8.  Plasminogen Activator Inhibitor-1 (PAI-1) gene 4G/5G alleles frequency distribution in the Lebanese population.

Authors:  Dina M R Shammaa; Amira S Sabbagh; Ali T Taher; Ghazi S Zaatari; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2007-06-20       Impact factor: 2.316

Review 9.  Thrombolytic therapy in the treatment of stroke.

Authors:  G J del Zoppo
Journal:  Drugs       Date:  1997       Impact factor: 9.546

10.  Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1.

Authors:  Lakshmi Venkatraman; Ser-Mien Chia; Balakrishnan Chakrapani Narmada; Jacob K White; Sourav S Bhowmick; C Forbes Dewey; Peter T So; Lisa Tucker-Kellogg; Hanry Yu
Journal:  Biophys J       Date:  2012-09-05       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.